# tislelizUMaB in canceR Patients With molEcuLar residuaL Disease

Source: https://onco.cc/trials/nct06332274/  
OnCo record `nct06332274` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of tislelizumab in pancreatic cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.

## Summary

tislelizUMaB in canceR Patients With molEcuLar residuaL Disease is a phase 3, randomised interventional study registered as NCT06332274 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 717 participants, started 2025-04-16 and due to reach its primary completion in 2029-04. Interventions recorded: Tislelizumab; Blood sampling; Placebo. Conditions listed: Cancer; Lung Cancer; Colo-rectal Cancer; Pancreas Cancer; Soft Tissue Sarcoma. Primary outcome: Efficacy of tislelizumab compared to placebo as measured by DFS (Disease-free survival). Pancreatic eligibility wording from the registry: "Histology: TNM stage II-III NSCLC, Stage II-III colorectal cancer, stage I-III pancreatic cancer, grade 3 limb or trunk wall soft-tissue sarcoma". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: UMBRELLA
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06332274
- Phase: 3
- Setting: tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
- Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Enrolled: 717

## Sources

- ClinicalTrials.gov NCT06332274: https://clinicaltrials.gov/study/NCT06332274

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06332274.json